HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DYSPORT® safely and effectively. See full prescribing information for DYSPORT®.

First Page		Document Content
Date: 2016-01-21 16:59:43 Neurology Neurological disorders Botulinum toxin Botulism Dystonia Spasmodic torticollis Wrinkle Hyperhidrosis Spasticity Neurotoxin Ptosis Torticollis		HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DYSPORT® safely and effectively. See full prescribing information for DYSPORT®. Add to Reading List Source URL: www.galdermausa.com Download Document from Source Website File Size: 904,79 KB Share Document on Facebook

	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DYSPORT® safely and effectively. See full prescribing information for DYSPORT®. DocID: 1oBwA - View Document
	BLA STNFDA APPROVED LABELING TEXT HIGHLIGHTS OF PRESCRIBING INFORMTION These highlights do not include all the information needed to use . Blepharospasm: 1.25 Units-2.5 Units into each of 3 sites per affec DocID: 1nR51 - View Document
	ATTACHMENT # 2 to the UNOPPOSED MOTION OF THE NATIONAL SPASMODIC TORTICOLLIS ASSOCIATION, THE NATIONAL SPASMODIC DYSPHONIA ASSOCIATION, ALLIED EDUCATIONAL FOUNDATION, AND WASHINGTON LEGAL FOUNDATION FOR LEAVE TO FILE AS DocID: 1l2Ba - View Document
	Clostridium botulinum neurotoxin type A (Xeomin) for sialorrhoea associated with adult Parkinson’s disease and paediatric cerebral palsy DocID: 1fM0Q - View Document
	PRESS RELEASE MERZ NEUROSCIENCES TO PRESENT KEY CLINICAL DATA AT THE ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN) DocID: 1a1Yq - View Document